TP53 and myelodysplastic syndrome: Our results demonstrated that patients with MDS accompanied by TP53 abnormalities who underwent allo-HSCT trended to show better survival than those who only received HMAs or venetoclax-based treatments, but this advantage was limited and not as good as that in patients without TP53 abnormalities, as reported previously (34).